JP2011515497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515497A5 JP2011515497A5 JP2011502076A JP2011502076A JP2011515497A5 JP 2011515497 A5 JP2011515497 A5 JP 2011515497A5 JP 2011502076 A JP2011502076 A JP 2011502076A JP 2011502076 A JP2011502076 A JP 2011502076A JP 2011515497 A5 JP2011515497 A5 JP 2011515497A5
- Authority
- JP
- Japan
- Prior art keywords
- expression product
- patient
- level
- hematological proliferative
- proliferative disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3970108P | 2008-03-26 | 2008-03-26 | |
| US61/039,701 | 2008-03-26 | ||
| PCT/US2009/038462 WO2009120905A2 (en) | 2008-03-26 | 2009-03-26 | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515497A JP2011515497A (ja) | 2011-05-19 |
| JP2011515497A5 true JP2011515497A5 (enExample) | 2013-05-23 |
Family
ID=41114735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502076A Withdrawn JP2011515497A (ja) | 2008-03-26 | 2009-03-26 | 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US8709715B2 (enExample) |
| EP (2) | EP2271672B1 (enExample) |
| JP (1) | JP2011515497A (enExample) |
| CN (1) | CN102046660A (enExample) |
| WO (3) | WO2009120905A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| WO2012098407A1 (en) | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013023015A2 (en) * | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| US10196614B2 (en) | 2012-09-18 | 2019-02-05 | University Of Washington Through Its Center For Commercialization | Compositions and methods for antigen targeting to CD180 |
| US20150315279A1 (en) * | 2012-12-21 | 2015-11-05 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| US10066014B2 (en) * | 2014-02-06 | 2018-09-04 | Yeda Research And Development Co. Ltd. | Anti CD84 antibodies, compositions comprising same and uses thereof |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| AU2015346460A1 (en) | 2014-11-10 | 2017-03-23 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| CA3218106A1 (en) | 2015-03-06 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| BR112017020952A2 (pt) * | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| US20170121420A1 (en) | 2015-11-02 | 2017-05-04 | Janssen Pharmaceutica Nv | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
| WO2017191627A1 (en) * | 2016-05-02 | 2017-11-09 | Ramot At Tel-Aviv University Ltd. | Antibodies to interleukin 13 receptor alpha-1 (il-13r alpha 1) and uses thereof |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| MX389710B (es) | 2016-05-27 | 2025-03-20 | Agenus Inc | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. |
| CN106831998B (zh) * | 2016-06-22 | 2020-09-15 | 徐州医科大学 | 一种人il1rap特异性car及其应用 |
| SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| US10253371B2 (en) * | 2016-08-29 | 2019-04-09 | National Guard Health Affairs | Method of treating leukemia based on gene expression of clock genes |
| CA3084459A1 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| JP7304287B2 (ja) | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| WO2020028784A1 (en) * | 2018-08-03 | 2020-02-06 | The Trustees Of Indiana University | Methods for targeting, inhibiting, and treating a tumor microenvironment |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| CN113727999A (zh) | 2019-01-11 | 2021-11-30 | 奥默罗斯公司 | 用于治疗癌症的方法和组合物 |
| JP7767298B2 (ja) | 2020-03-13 | 2025-11-11 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| US20220193238A1 (en) * | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Anti-il5r antibody formulations |
| CN113238061B (zh) * | 2021-07-09 | 2021-10-01 | 中南大学湘雅医院 | 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用 |
| CN113408480B (zh) * | 2021-07-13 | 2022-09-30 | 上海交通大学医学院附属瑞金医院 | 基于骨髓细胞形态学的血液疾病人工智能辅助诊断系统 |
| EP4590704A1 (en) | 2022-09-21 | 2025-07-30 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
| CN119786008B (zh) * | 2024-11-13 | 2025-11-14 | 南阳市中心医院 | 基于血液中生物标志物预测烟雾病的临床决策支持方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| PE64396A1 (es) * | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| US6974682B1 (en) * | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| AU2001247616B2 (en) * | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070292970A1 (en) * | 2003-11-04 | 2007-12-20 | Martin Dugas | Method for Distinguishing Aml-Specific Flt3 Length Mutations From Tkd Mutations |
| MXPA06014065A (es) * | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| RU2007130722A (ru) * | 2005-02-16 | 2009-03-27 | Вайет (Us) | Способы и устройства для диагностики, прогнозирования и выбора лечения лейкоза |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| WO2007004060A2 (en) * | 2005-05-05 | 2007-01-11 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7560530B1 (en) * | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| CA3108119C (en) * | 2008-01-15 | 2024-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| CA2750818A1 (en) * | 2009-01-27 | 2010-08-05 | Proteogenix, Inc. | Biomarkers for detection of neonatal sepsis in biological fluid |
| ES2571235T3 (es) * | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2011155607A1 (ja) * | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| UY33827A (es) * | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
| WO2012088290A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| WO2012098407A1 (en) | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| CN103492416A (zh) | 2011-04-15 | 2014-01-01 | 默克专利股份公司 | 用于癌症中使用的抗il-1r1抑制剂 |
| CN103608030A (zh) | 2011-06-21 | 2014-02-26 | 昂科发克特公司 | 用于治疗和诊断癌症的组合物和方法 |
| WO2013023015A2 (en) | 2011-08-11 | 2013-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
-
2009
- 2009-03-26 CN CN2009801190867A patent/CN102046660A/zh active Pending
- 2009-03-26 JP JP2011502076A patent/JP2011515497A/ja not_active Withdrawn
- 2009-03-26 US US12/934,120 patent/US8709715B2/en active Active
- 2009-03-26 EP EP09725022.9A patent/EP2271672B1/en not_active Not-in-force
- 2009-03-26 WO PCT/US2009/038462 patent/WO2009120905A2/en not_active Ceased
- 2009-03-26 US US12/810,006 patent/US20110044894A1/en not_active Abandoned
- 2009-03-26 WO PCT/US2009/038459 patent/WO2009120903A2/en not_active Ceased
- 2009-03-26 EP EP09726329.7A patent/EP2271673B1/en not_active Not-in-force
- 2009-03-26 WO PCT/US2009/038455 patent/WO2009120899A2/en not_active Ceased
-
2013
- 2013-02-11 US US13/764,492 patent/US8715619B2/en active Active
-
2014
- 2014-04-03 US US14/244,698 patent/US9371390B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020283A (ja) | 血液悪性腫瘍を処置するための抗ｌａｇ－３抗体 | |
| JP7480248B2 (ja) | 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ | |
| Linley et al. | Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells | |
| KR102416144B1 (ko) | 환자에서 항-cd19 치료법의 치료 이익의 예측 방법 | |
| KR20140031905A (ko) | 다발성 골수종 환자에 대한 bcma-기본 계층화 및 치료법 | |
| JP2017079753A (ja) | ＣＤ１９ｘＣＤ３二重特異性抗体を投与するための投与計画 | |
| Ribas et al. | Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion | |
| JP2023083424A (ja) | 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ | |
| Chavez et al. | Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma | |
| Yin et al. | RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response | |
| Sotomayor et al. | Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy | |
| KR20230038318A (ko) | 불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단 | |
| CN119798437A (zh) | 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗 | |
| WO2012142411A1 (en) | Systems and methods for detecting hent1 expression in hematological disorders | |
| Shree et al. | A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade b-cell lymphoma highlights challenges in translation from mouse to human studies | |
| Ladányi et al. | Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab | |
| Hock et al. | Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies | |
| JP2018528213A5 (enExample) | ||
| Schwickart et al. | Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI 3185, a fully human antibody to CXCR 4 | |
| WO2018200473A1 (en) | Detection and targeting of tumor-promoting neutrophils cross-reference to related applications | |
| JP6571660B2 (ja) | 抗体の分析 | |
| JP6195716B2 (ja) | 抗癌剤耐性診断マーカー | |
| AU2024247883A1 (en) | Methods of treating melanoma using an anti-ctla4 antibody | |
| EP4302092A1 (en) | Novel biomarkers and uses thereof | |
| HK40103499A (zh) | 针对血液恶性肿瘤的cd47靶向疗法的给药参数 |